drugset / Trial / NCT04893174

Mesenchymal Stem Cells for The Treatment of Knee Osteoarthritis (KOA).

NCT04893174

Phase 1 Unknown 6 enrolled Meridigen Biotech Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

The clinical study with UMC119-06-05 is designed to investigate the safety in patients with mild to moderate knee osteoarthritis (KOA). This will be a dose escalation, open label, single-center study in adult with mild to moderate knee osteoarthritis. UMC119-06-05 is ex vivo cultured human umbilical cord tissue-derived mesenchymal stem cells product which is intended for treatment of knee osteoarthritis.

Timeline

Start
2022-09-15
Primary completion
2024-09
Completion
2025-06

Drugs

EvaluationDrugModalityDoseRoute
Subject human umbilical cord mesenchymal stem cells Cell therapy Other
Background Hyaluronic Acid Other / unclassified Other

Indications